Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00143247 · ClinicalTrials.gov registry record · Phase 2
Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 173
- Enrollment target
NCT00143247 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 173 participants.
The verdict
NCT00143247, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 173 participants
- Enrollment target
Study Summary
This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
Interventions
- DRUG Exubera® (inhaled insulin)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173 participants |
| Start Date | 2003-03 |
| Est. Completion | 2008-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00143247
The ClinicalTrials.gov registry entry for NCT00143247 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 173 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Exubera® (inhaled insulin) is the first listed.
NCT00143247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00143247 about?
NCT00143247 is a clinical study titled "Long-Term Safety Study of Inhaled Insulin: An Up to Four-Year Extension of Therapy in Subjects With Type 1 or Type 2 Diabetes Mellitus". This is a long-term safety study for Phase 2 subjects who choose to remain on Exubera® (inhaled insulin).
What is the current status of trial NCT00143247?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 173 participants. The study started on 2003-03. Estimated completion is 2008-01.
What interventions are being tested in trial NCT00143247?
The interventions under investigation include: Exubera® (inhaled insulin) (DRUG).
Who is sponsoring clinical trial NCT00143247?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.